B+
Bull case
25%
Probability
Target price
$58.00
+26.4% vs current
ACU
Acme UnitedANYSE American / Health Care Equipment & Services
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$52.00
+13.3% vs current
B-
Bear case
25%
Probability
Target price
$39.00
-15.0% vs current
AI sentiment snapshot
Latest data as of 2026-07-15
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+56.1
Score
AI commentary
Tone is mixed: the primary earnings filing confirms strong sales growth and strategic investments, but also confirms weaker Q1 earnings from tariff-related costs and higher expenses [#SEC-8K-2026-04-23]. News coverage is thin, social coverage is unavailable, and analyst revisions or a reliable post-release price reaction are not provided. The setup remains a low-conviction monitoring story.
RankAlpha Sentiment Codex - 2026-07-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystTariff-loaded inventory burn-off may support margin recoveryMedium impact
Q1 profitability was pressured by tariff-related costs as higher-cost inventory was sold; management also characterized Med-Nap quality-assurance spending as non-recurring [#SEC-8K-2026-04-23]. Recovery remains a monitoring thesis rather than confirmed guidance.
2026-12-31eventMyMedic integration and seasonal contributionHigh impact
MyMedic contributed to Q1 sales growth but had minimal earnings impact because of seasonality. Management cited retail expansion, purchasing synergies, overhead reduction, and function consolidation as potential earnings drivers, with most profitability expected in Q4 [#SEC-8K-2026-04-23].
2027-03-31catalystFacility consolidation and automation operating leverageHigh impact
The company cited a new Spill Magic facility, Canadian site consolidation, and ongoing automation as initiatives intended to lower expenses and expand capacity. Execution benefits are not yet demonstrated in the available evidence [#SEC-8K-2026-04-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-15 • Updated nightlySource: Internal modelMethodology